Hung-jen Chen

Taitung, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Regarding Dähler K et al. '' Evaluation of the prognostic value of the ESTRO/EORTC classification of reirradiation in patients with non-small cell lung cancer".

Regarding Dähler K et al. '' Evaluation of the prognostic value of the ESTRO/EORTC classification of reirradiation in patients with non-small cell lung cancer".

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: September 05, 2025

Real-World Evidence That Non-Smokers With High PD-L1 Non-Squamous NSCLC Have Poorer Outcomes With Immune Checkpoint Inhibitors.

Real-World Evidence That Non-Smokers With High PD-L1 Non-Squamous NSCLC Have Poorer Outcomes With Immune Checkpoint Inhibitors.

Journal: Thoracic cancer

Published: June 17, 2025

Efficacy of Respiration-controlled Radiotherapy Among Patients With Locally Advanced-stage Lung Cancer: A Population-based Study.

Efficacy of Respiration-controlled Radiotherapy Among Patients With Locally Advanced-stage Lung Cancer: A Population-based Study.

Journal: Anticancer research

Published: June 18, 2024

Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early-stage non-small-cell lung cancer: a population-based study.

Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early-stage non-small-cell lung cancer: a population-based study.

Journal: Thoracic cancer

Published: May 14, 2024

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.

Journal: BMC pulmonary medicine

Published: January 14, 2024

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.

Journal: BMC cancer

Published: December 29, 2023

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.

Journal: Cancer medicine

Published: July 03, 2023

Geographic characteristics of HTLV-1 molecular subgroups and genetic substitutions in East Asia: Insights from complete genome sequencing of HTLV-1 strains isolated in Taiwan and Japan.

Geographic characteristics of HTLV-1 molecular subgroups and genetic substitutions in East Asia: Insights from complete genome sequencing of HTLV-1 strains isolated in Taiwan and Japan.

Journal: PLoS neglected tropical diseases

Published: May 01, 2023

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.

Journal: BMC cancer

Published: April 27, 2023

Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study.

Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study.

Journal: Cancers

Published: December 04, 2022

The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer.

The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: November 15, 2022

Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis.

Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis.

Journal: Thoracic cancer

Published: April 05, 2022

Showing 1-12 of 46

Last Updated: 09/26/2026